HBIO vs MLAB

For growth investors, Mesa Laboratories, Inc.

(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Analysts rate Harvard Bioscience, Inc. (HBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesa Laboratories, Inc.

(MLAB) delivered a total return of -56. 5%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: MLAB returned +4. 5% versus HBIO's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mesa Laboratories, Inc.

(MLAB) is the lower-risk stock at 1. 78β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 14% more volatile than MLAB relative to the S&P 500. On balance sheet safety, Mesa Laboratories, Inc. (MLAB) carries a lower debt/equity ratio of 114% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesa Laboratories, Inc.

(MLAB) is pulling ahead at 11. 5% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mesa Laboratories, Inc.

(MLAB) is the more profitable company, earning -0. 8% net margin versus -65. 5% for Harvard Bioscience, Inc. — meaning it keeps -0. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLAB leads at 6. 8% versus -0. 7% for HBIO. At the gross margin level — before operating expenses — MLAB leads at 62. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MLAB: -11.

4% to $94. 00.

In this comparison, MLAB (0.

6% yield) pays a dividend. HBIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mesa Laboratories, Inc.

(MLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLAB: +4. 5%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HBIO (Healthcare) and MLAB (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

MLAB pays a dividend while HBIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.